Last reviewed · How we verify
MenAC conjugate vaccine
MenAC conjugate vaccine is a Conjugate vaccine Biologic drug developed by Sanofi. It is currently in Phase 3 development for Prevention of meningococcal disease caused by Neisseria meningitidis serogroups A and C.
MenAC conjugate vaccine stimulates the immune system to produce antibodies against meningococcal serogroups A and C by conjugating polysaccharide antigens to a protein carrier.
MenAC conjugate vaccine stimulates the immune system to produce antibodies against meningococcal serogroups A and C by conjugating polysaccharide antigens to a protein carrier. Used for Prevention of meningococcal disease caused by Neisseria meningitidis serogroups A and C.
At a glance
| Generic name | MenAC conjugate vaccine |
|---|---|
| Sponsor | Sanofi |
| Drug class | Conjugate vaccine |
| Target | Neisseria meningitidis serogroups A and C capsular polysaccharides |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains purified capsular polysaccharides from Neisseria meningitidis serogroups A and C that are covalently linked to a protein carrier (typically diphtheria or tetanus toxoid). This conjugation enhances immunogenicity by converting T-cell-independent antigens into T-cell-dependent antigens, resulting in stronger and more durable antibody responses and immunological memory compared to unconjugated polysaccharide vaccines.
Approved indications
- Prevention of meningococcal disease caused by Neisseria meningitidis serogroups A and C
Common side effects
- Injection site pain/erythema
- Fever
- Myalgia
- Headache
Key clinical trials
- Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in China (PHASE3)
- Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m (PHASE3)
- Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children (PHASE3)
- Safety Study of a Vaccine Against Meningitis in Infants ( 2,4 & 6 Months Age) After a Birth Dose of Hepatitis B. (PHASE3)
- Safety Study of a Vaccine Against Meningitis in Infants (2,4 & 6 Months Age) After a Birth Dose of Hepatitis B. (PHASE3)
- Immunogenicity and Safety of Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine in Infants 2 to 5 Months of Age (PHASE1, PHASE2)
- Assess the Immune Response Following Primary Vaccination With GSK Biologicals' Tritanrix™-HepB/Hib-MenAC vs Tritanrix™-HepB/Hiberix™ Given at 6,10 & 14 Wks of Age to Infants Who Received Hepatitis B Vaccine at Birth (PHASE3)
- Immunogenicity & Safety Study of a Vaccine Against Meningitis in Infants (2,4,6 Months) After a Hepatitis B Birth Dose. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MenAC conjugate vaccine CI brief — competitive landscape report
- MenAC conjugate vaccine updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about MenAC conjugate vaccine
What is MenAC conjugate vaccine?
How does MenAC conjugate vaccine work?
What is MenAC conjugate vaccine used for?
Who makes MenAC conjugate vaccine?
What drug class is MenAC conjugate vaccine in?
What development phase is MenAC conjugate vaccine in?
What are the side effects of MenAC conjugate vaccine?
What does MenAC conjugate vaccine target?
Related
- Drug class: All Conjugate vaccine drugs
- Target: All drugs targeting Neisseria meningitidis serogroups A and C capsular polysaccharides
- Manufacturer: Sanofi — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of meningococcal disease caused by Neisseria meningitidis serogroups A and C